183 related articles for article (PubMed ID: 15547525)
1. The epigenetics of ovarian cancer drug resistance and resensitization.
Balch C; Huang TH; Brown R; Nephew KP
Am J Obstet Gynecol; 2004 Nov; 191(5):1552-72. PubMed ID: 15547525
[TBL] [Abstract][Full Text] [Related]
2. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
3. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment.
Zhou XC; Dowdy SC; Podratz KC; Jiang SW
Gynecol Oncol; 2007 Oct; 107(1):143-53. PubMed ID: 17692907
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
[TBL] [Abstract][Full Text] [Related]
7. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
8. New anti-cancer strategies: epigenetic therapies and biomarkers.
Balch C; Montgomery JS; Paik HI; Kim S; Kim S; Huang TH; Nephew KP
Front Biosci; 2005 May; 10():1897-931. PubMed ID: 15769674
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism of multidrug resistance of ovarian cancer].
Miedzińska-Maciejewska M; Wcisło G
Przegl Lek; 2002; 59(10):854-8. PubMed ID: 12632928
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract][Full Text] [Related]
15. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
16. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
18. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
Camci C; Sevinc A; Aslan Y; Kalender ME; Buyukberber S
Cancer Chemother Pharmacol; 2009 Mar; 63(4):745-8. PubMed ID: 18504578
[TBL] [Abstract][Full Text] [Related]
19. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer: a focus on management of recurrent disease.
Herzog TJ; Pothuri B
Nat Clin Pract Oncol; 2006 Nov; 3(11):604-11. PubMed ID: 17080178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
